RT Journal Article
SR Electronic
T1 A Retrospective Study to Determine the Impact of Psychedelic Therapy for Dimensional Measures of Wellness: A Qualitative Analysis of Response Data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.12.23285814
DO 10.1101/2023.02.12.23285814
A1 Virgilio, Victoria Di
A1 Minerbi, Amir
A1 Fletcher, Jenna
A1 Virgilio, Anthony Di
A1 Aggerwal, Salena
A1 Sheen, Luke
A1 Deol, Jagpaul Kaur
A1 Gupta, Gaurav
YR 2023
UL http://medrxiv.org/content/early/2023/02/15/2023.02.12.23285814.abstract
AB Background The World Health Organization (WHO) defines wellness as the optimal state of health of individuals and groups. No study to date has identified the impact of psychedelic medicines for optimizing wellness using a dimensional approach. Treatment effects can be measured more broadly using a composite score of participants’ global perceptions of change for pain, function, and mood scores. Given the precedence in previous work for retrospective study of participants’ self-medicating with these substances, the nature of this study design allows for a safe way to develop further evidence in this area of care, with wellness as the broad indication.Methods 65 civilian or military veterans between the ages of 18-99 self-identifying as having used psychedelic medicines for non-recreational therapeutic purposes in the last 3 years were recruited for this study. Participants completed various standardized questionnaires that will be analyzed in a separate study, while this study analyzed the qualitative experiences described in relation to the medicines used and coded them according to themes developed from review of previous literature.Results A total of 93 comments were analyzed. Participant comments were classified into these categories: mysticism and spirituality, functional improvement and self awareness, social connection and cultural impact, impact on medical and mental health conditions, neutral impressions, sensations or difficult experiences. Participants described impacts in these categories related to spiritual, physiological, psychological, and social improvements, as well as difficulties and complex emotions regarding the experience of using psychedelic medicines.Discussion Wellness of individuals or groups is not simply an absence of disease, symptoms, or impairments. Rather, it reflects the outcome of numerous personal characteristics, psychophysiology, and choices, expressed throughout one’s lifespan, unfolding in dynamic interaction with a complicated socio-cultural and physical environment. Participants that used psychedelic medicines described improvement of medical and mental health conditions, social interaction, spirituality, and overall function. In general, quality of life and wellness consequently improved after the use of these medicines based on established multidimensional factors.Conclusion The use of various psychedelic medicines appears to be associated with a broad range of qualitative experiences that could help clarify the mechanism of how they impact wellness in the future.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05469243Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Chair, DRDC Human Research Ethics Committee, email: HREC-CEESH-Toronto@drdc.rddc.gc.ca ; (416) 635-2000, ext. 3141. 1133 Sheppard Avenue West Toronto, Ontario, M3K 2C9I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript